FDA approves Imfinzi plus chemotherapy for advanced biliary tract cancer

The FDA approved durvalumab with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer.Durvalumab (Imfinzi, AstraZeneca) — a PD-L1 checkpoint inhibitor — is approved in the United States for treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after chemoradiotherapy. It also is approved for treatment of extensive-stage small cell lung cancer.The FDA based approval of the biliary tract cancer indication on results of the randomized phase 3 TOPAZ-1 trial.The international, double-blindRead More